-
-
-
Time period and age groups Number of IgM positive cases n/N P value Number of IgG positive cases n/N P value Male Female Total Male Female Total May–June 2020 Under 18 1/51
(1.96%)0/32
(0.0%)1/83
(1.2%)0.42 3/51
(5.8%)5/32
(15.6%)8/83
(9.6%)0.26 19–34 3/103
(12.5%)2/71
(2.8%)5/174
(2.8%)0.65 10/103
(9.7%)3/71
(4.2%)13/174
(7.4%)0.38 35–49 5/141
(3.5%)5/67
(7.4%)10/208
(4.8)0.34 12/141
(8.5%)2/67
(2.9%)14/208
(6.7%)0.15 50–64 3/40
(7.5%)5/42
(12%)8/82
(9.8%)0.5 7/40
(17.5%)11/42
(26.1%)18/82
(21.9%)0.34 ≥ 65 1/14
(7.14%)1/12
(8.3%)2/26
(7.7%)0.9 1/14
(7.1%)2/12
(16.6%)3/26
(11.5%)0.5 July–August 2020 Under18 1/67
(1.4%)3/67
(4.4%)4/135
(3%)0.8 16/67
(23.8%)10/67
(14.9%)26/135
(19.2%)0.5 19–34 15/171
(8.8%)12/196
(6.1%)27/363
(7.4%)0.3 21/171
(12.2%)18/196
(9.1%)39/363
(10.7%)0.6 35–49 43/217
(19.8%)20/209
(9.5%)63/426
(15%)0.01 47/217
(21.6%)40/209
(19.1%)87/426
(20.4%)0.7 50–64 22/104
(21%)20/103
(19%)42/207
(20%)0.7 36/104
(34.6%)30/103
(29.1%)66/207
(31.8%)0.2 ≥ 65 6/38
(15.7%)13/52
(25%)19/90
(21%)0.4 10/38
(26.3%)21/52
(40.3%)31/90
(34.4%)0.16 September–October 2020 Under18 9/67
(13%)1/57
(1.8%)10/124
(8%)0.02 19/67
(28.3%)11/57
(19.2%)30/124
(24.1%)0.29 19–34 33/187
(17.7%)29/204
(14.2%)62/391
(15.8%)0.12 50/187
(26.7%)60/203
(29.5%)110/390
(28.2%)0.07 35–49 50/234
(21.3%)45/211
(21.3%)95/445
(21.3%)0.6 73/234
(31.1%)74/211
(35%)147/444
(33%)0.52 50–64 37/114
(32.4%)42/151
(27.8%)79/265
(29.8%)0.12 43/114
(37.7%)65/151
(43%)108/265
(40.7%)0.61 ≥ 65 39/79
(49.3%)22/85
(25.8%)55/164
(33.5%)0.03 38/79
(48%)34/85
(40%)72/164
(43.9%)0.38 November–December 2020 Under18 4/33
(12.1%)3/27
(11.1%)7/60
(11.6%)0.9 11/33
(33.3%)7/27
(25.9%)18/60
(30%)0.51 19–34 27/134
(20.1%)16/157
(10.1%)43/291
(14.7%)0.07 53/134
(39.5%)54/157
(34.3%)107/291
(36.7%)0.51 35–49 34/170
(20%)35/181
(19.3%)69/351
(19.6%)0.98 61/170
(35.8%)86/181
(47.5%)147/351
(41.8%)0.04 50–64 37/106
(34.9%)45/154
(29.2%)82/260
(31.5%)0.62 61/106
(57.5%)82/154
(53.2%)143/260
(55%)0.76 ≥ 65 31/53
(58.4%)28/59
(47.4%)59/112
(52.6%)0.33 41/53
(77.3%)36/59
(61%)77/112
(68.7%)0.08 January–February 2021 Under18 0/12
(0%)0/8
(0%)0/20
(0%)0.4 3/12
(25%)2/8
(25%)5/20
(25%)1 19–34 4/36
(11.1%)1/40
(2.5%)5/76
(6.5%)0.09 13/36
(36.1%)15/40
(37.5%)28/76
(36.8%)0.83 35–49 6/43
(13.9%)3/60
(5%)9/103
(8.7%)0.11 17/43
(39.5%)16/60
(26.6%)33/103
(32%)0.38 50–64 2/26
(7.6%)5/37
(13.5%)7/63
(11.1%)0.75 9/26
(34.6%)15/37
(40.5%)24/63
(38%)0.22 ≥ 65 3/11
(27.2%)3/21
(14.2%)6/32
(18.7%)0.53 6/11
(54.5%)10/21
(47.6%)16/32
(50%)0.71 March–April 2021 Under18 0/8
(0%)2/10
(20%)2/18
(11.1%)0.18 2/8
(25%)3/10
(30%)5/18
(27.7%)0.61 19–34 5/62
(8%)5/67
(7.4%)10/129
(7.7%)0.9 9/62
(14.5%)8/67
(11.9%)17/129
(13.1%)0.78 35–49 12/74
(16.2%)2/65
(3%)14/139
(10%)0.01 21/74
(28.3%)13/65
(20%)34/139
(24.4%)0.47 50–64 5/22
(22.7%)2/29
(6.8%)7/51
(13.7%)0.12 10/22
(45.4%)8/29
(27.5%)18/51
(35.2%)0.17 ≥ 65 8/11
(72.7%)4/19
(21%)12/30
(40%)0.00 10/11
(90.9%)8/19
(42.1%)18/30
(60%)0.03 n: number of positive cases, N: total number of cases. Table 1. SARS-CoV-2 IgM and IgG seroprevalence based on the age groups and sex from May 1 2020 to April 30 2021 in Tehran, Iran.
Figure 2 个
Table 1 个
